{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Dexmedetomidine and Propofol in Hysteroscopic Surgery"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 150 patients aged 18-60 years with ASA status I-II undergoing hysteroscopic surgery"
      },
      "Participants": {
        "score": 2,
        "evidence": "150 patients aged 18-60 years with ASA status I-II undergoing hysteroscopic surgery at the Affiliated Hospital of North Sichuan Medical College"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomly assigned to receive dexmedetomidine at 0.4, 0.6, 0.8, or 1.0 \u00b5g/kg, or saline"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to determine the optimal dose of dexmedetomidine combined with propofol for hysteroscopic surgery"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the EC50 of propofol, measured intraoperatively"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using SPSS software, and allocation was concealed"
      },
      "Blinding": {
        "score": 2,
        "evidence": "Both patients and clinicians were blinded"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "150 patients aged 18-60 years with ASA status I-II undergoing hysteroscopic surgery"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "The EC50 of propofol was significantly lower in the Dex 0.6, Dex 0.8, and Dex 1.0 groups compared to the saline group"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "The EC50 of propofol was significantly lower in the Dex 0.6, Dex 0.8, and Dex 1.0 groups compared to the saline group (p < 0.05)"
      },
      "Harms": {
        "score": 1,
        "evidence": "Higher dexmedetomidine doses reduced propofol requirements and respiratory depression incidence (p < 0.01) but increased bradycardia incidence (p = 0.02)"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: ChiCTR2000033220"
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified"
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}